Last reviewed · How we verify
NCT06638034
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
EARLY_PHASE1 trial testing 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy in FAP- Expressing Positive Tumors in 15 participants. Currently enrolling.
1 January 2025
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 May 2024 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 February 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy — full drug profile →
Conditions studied
- FAP- Expressing Positive Tumors — all drugs for FAP- Expressing Positive Tumors →
- RGD- Expressing Positive Tumors — all drugs for RGD- Expressing Positive Tumors →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 90, any sex, with FAP- Expressing Positive Tumors or RGD- Expressing Positive Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
FAP and RGD are overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-FAPI-RGD--a new dual-targeted 177Lu therapeutic drug for the first time in the world.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic potential of FAPI RLT in oncology: A systematic review.
Ruzzeh S, Abdlkadir AS, Paez D, Kang KW, et al · · 2025 · cited 18× · PMID 40213678 · DOI 10.7150/thno.106108 -
Radioligand Therapy in Cancer Management: A Global Perspective.
Ninatti G, Lee ST, Scott AM. · · 2025 · cited 5× · PMID 41228206 · DOI 10.3390/cancers17213412 -
Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials.
Palihati M, Das JP, Yeh R, Capaccione K. · · 2025 · cited 5× · PMID 40863874 · DOI 10.3390/tomography11080083 -
Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP.
Lee EJ, Chung HW, So Y, Kim IA, et al · · 2025 · cited 1× · PMID 40805245 · DOI 10.3390/cancers17152549 -
Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors.
Wu X, Wang Y, Li Y, Hu W. · · 2025 · PMID 41425958 · DOI 10.3389/fnume.2025.1737443
Verify or expand the search:
- PubMed search for NCT06638034
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06638034 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06638034.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing